Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$31.7M
56M shares
52-week range
$0.48 – $4.00
3% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
www.heartbeam.comNo one on the platform currently holds BEAT.
No tracked institution reports a position in BEAT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2005-08-18 | 1-for-10reverse |
No one on the platform has traded BEAT yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$BEAT Solid progress under the hood on today's Q2 call: • Initial orders SHIPPED for the HeartBeam 3D ECG Card & commercial onboarding active • Cost discipline: Q4 cash burn dropping below $2.5M/qtr (FY26 burn <$14M) • ALIGN-ACS pilot study patient enrollment completed ahead of schedule (134 pts); full data readout at TCT late Oct! • FDA pre-sub submitted for heart attack detection; pivotal trial launch targeted before year-end • Cash balance at $8.8M extending runway into 2027 Commercial momentum building into Q3. Chart holding support nicely around .58 despite intraday noise. Fundamental thesis intact! 🍾🚀🍾🚀💰💰💰💰
View on StockTwits ↗$BEAT i was a patient managed by a concierge…was…that yahoo touted this shit and he was fired as i lost a ton…as a patient i am not spending money for a device to manage me when i am spending money for an expert to manage me…this should be bundled in their service…what is this company doing to ensure this happens? btw i will send them a bill for my advice
View on StockTwits ↗$BEAT is it me or should the BOD tell this guy who touts he developed the product and company to step down. anyone else think he is the contributing factor as to why we lost our investment money and this company is going no where???
View on StockTwits ↗$BEAT Listen to the earnings call for the nice and tight VAGENDA at 18:20.
View on StockTwits ↗$BEAT These clowns. Dancing around the real questions that all investors have. I’m so tired of these calls and for years they do nothing but stroke their own egos and try to pimp their products. If it is sooo good and soooo revolutionary then why is your stock 50 cents? There is no institution that gives a damn about your products. Sounds like the future is hanging on what transpires in Indonesia? WTF. 75 days the hear something from the FDA? They will most likely take all 75 of those days. Then another study? They will run out of cash by the end of the year. So, unless they enroll 30k patients in the next 90 days they will probably R/S and then dilute again. F me. What a turd.
View on StockTwits ↗$BEAT we need an upgrade and a stock price hike.
View on StockTwits ↗$BEAT Did anyone else catch the part about the CEO transition on the earnings. If they didn't do it they'd still be in R&D phase. So, they did it and that's why this quarter earnings isn't a beat. Otherwise it would have been because the outgoing CEO severance package. So much in stock and so much in cash benefit. I took a screenshot of that slide.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.